MyMedR

Displaying all 5 publications

Abstract:

Sort:

Erratum: MEI-YING LIN amp; SI-QIN GE (2021) Tsounkranaglenea hefferni gen. et sp. nov. from Sabah, Malaysia (Coleoptera, Cerambycidae, Lamiinae: Saperdini). Zootaxa, 5048: 289297

Lin MY, Ge SQ

Zootaxa, 2021 Nov 02;5060(4):599.
PMID: 34810644 DOI: 10.11646/zootaxa.5060.4.10
Tsounkranaglenea hefferni gen. et sp. nov. from Sabah, Malaysia (Coleoptera, Cerambycidae, Lamiinae: Saperdini)

Lin MY, Ge SQ

Zootaxa, 2021 Oct 06;5048(2):289-297.
PMID: 34810800 DOI: 10.11646/zootaxa.5048.2.9

A new saperdine species belonging to a new genus, Tsounkranaglenea hefferni gen. et sp. nov., is described from Sabah, Malaysia. The new genus differs from other genera of the tribe Saperdini by the special male sternite VII modified into a rake-shape, with the apex of the ventral plate of the median lobe unusually emarginated.
Fulltext Peak expiratory flow rate and sarcopenia risk in older Indonesian people: A nationwide survey

Ridwan ES, Wiratama BS, Lin MY, Hou WH, Liu MF, Chen CM, et al.

PLoS One, 2021;16(2):e0246179.
PMID: 33561132 DOI: 10.1371/journal.pone.0246179

Reduced peak expiratory flow is a common physiological change in older individuals and age is an important predictor for sarcopenia. We analyzed nationwide survey data to determine the relationship between peak expiratory flow rate and sarcopenia in older Indonesians. Community-dwelling Indonesian individuals aged ≥60 years (n = 2422; mean age = 67.21 y) from the fifth-wave data of the Indonesian Family Life Survey was selected. Sarcopenia was diagnosed based on handgrip strength, gait speed, and appendicular skeletal muscle mass measurements. Peak expiratory flow rates (PEFRs) were categorized according to their percentage of predicted flow rates as <50%, 50% to 80%, and >80%. Confounders previously determined to be associated with sarcopenia occurrence were included. Sarcopenia prevalence was 50.25%. After adjustment for confounders, PEFRs of <50% and 50% to 80% were associated with an increased sarcopenia risk (odds ratio = 5.22 and 1.88, respectively) compared with PEFRs of >80%. Poor lung function was independently associated with sarcopenia occurrence. Future studies should explore the usefulness of PEFR as a risk factor of sarcopenia.
American Brachytherapy Society: Brachytherapy treatment recommendations for locally advanced cervix cancer for low-income and middle-income countries

Suneja G, Brown D, Chang A, Erickson B, Fidarova E, Grover S, et al.

Brachytherapy, 2017 Jan-Feb;16(1):85-94.
PMID: 27919654 DOI: 10.1016/j.brachy.2016.10.007

PURPOSE: Most cervix cancer cases occur in low-income and middle-income countries (LMIC), and outcomes are suboptimal, even for early stage disease. Brachytherapy plays a central role in the treatment paradigm, improving both local control and overall survival. The American Brachytherapy Society (ABS) aims to provide guidelines for brachytherapy delivery in resource-limited settings.

METHODS AND MATERIALS: A panel of clinicians and physicists with expertise in brachytherapy administration in LMIC was convened. A survey was developed to identify practice patterns at the authors' institutions and was also extended to participants of the Cervix Cancer Research Network. The scientific literature was reviewed to identify consensus papers or review articles with a focus on treatment of locally advanced, unresected cervical cancer in LMIC.

RESULTS: Of the 40 participants invited to respond to the survey, 32 responded (response rate 80%). Participants were practicing in 14 different countries including both high-income (China, Singapore, Taiwan, United Kingdom, and United States) and low-income or middle-income countries (Bangladesh, Botswana, Brazil, India, Malaysia, Pakistan, Philippines, Thailand, and Vietnam). Recommendations for modifications to existing ABS guidelines were reviewed by the panel members and are highlighted in this article.

CONCLUSIONS: Recommendations for treatment of locally advanced, unresectable cervical cancer in LMIC are presented. The guidelines comment on staging, external beam radiotherapy, use of concurrent chemotherapy, overall treatment duration, use of anesthesia, applicator choice and placement verification, brachytherapy treatment planning including dose and prescription point, recommended reporting and documentation, physics support, and follow-up.
Fulltext Prevalence of chronic kidney disease in Asia: a systematic review and analysis

Liyanage T, Toyama T, Hockham C, Ninomiya T, Perkovic V, Woodward M, et al.

BMJ Glob Health, 2022 Jan;7(1).
PMID: 35078812 DOI: 10.1136/bmjgh-2021-007525

INTRODUCTION: The burden of chronic kidney disease (CKD) is growing rapidly around the world. However, there is limited information on the overall regional prevalence of CKD, as well as the variations in national prevalence within Asia. We aimed to consolidate available data and quantify estimates of the CKD burden in this region.
METHODS: We systematically searched MEDLINE, Embase and Google Scholar for observational studies and contacted national experts to estimate CKD prevalence in countries of Asia (Eastern, Southern and South Eastern Asia). CKD was defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 or the presence of proteinuria. For countries without reported data, we estimated CKD prevalence using agglomerative average-linkage hierarchical clustering, based on country-level risk factors and random effects meta-analysis within clusters. Published CKD prevalence data were obtained for 16 countries (of the 26 countries in the region) and estimates were made for 10 countries.
RESULTS: There was substantial variation in overall and advanced (eGFR <30 mL/min/1.73 m2) CKD prevalence (range: 7.0%-34.3% and 0.1%-17.0%, respectively). Up to an estimated 434.3 million (95% CI 350.2 to 519.7) adults have CKD in Asia, including up to 65.6 million (95% CI 42.2 to 94.9) who have advanced CKD. The greatest number of adults living with CKD were in China (up to 159.8 million, 95% CI 146.6 to 174.1) and India (up to 140.2 million, 95% CI 110.7 to 169.7), collectively having 69.1% of the total number of adults with CKD in the region.
CONCLUSION: The large number of people with CKD, and the substantial number with advanced CKD, show the need for urgent collaborative action in Asia to prevent and manage CKD and its complications.